Ryan D. Maynard
CIK: 0001363984
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 16, 2026IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Award(A)DirectDeferred Restricted Stock Unit
90.3K shares- - Feb 23, 2026FHTX
Foghorn Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
400K shares at avg. $5.75- - Jun 13, 2025IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Award(A)DirectDeferred Restricted Stock Unit
67.5K shares- - Nov 12, 2024IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Exercise(M)Direct50K shares at avg. $7.45$373K - Nov 12, 2024IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Sale(S)Direct50K shares at avg. $10.06$503K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  IOVA IOVANCE BIOTHERAPEUTICS, INC. | Award(A) Deferred Restricted Stock Unit | 90,316 | - | - | Direct |
| Feb 23, 2026 |  FHTX Foghorn Therapeutics Inc. | Award(A) Stock Option (right to buy) | 400,000 | $5.75 | - | Direct |
| Jun 13, 2025 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Award(A) Deferred Restricted Stock Unit | 67,546 | - | - | Direct |
| Nov 12, 2024 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Exercise(M) | 50,000 | $7.45 | $372,500 | Direct |
| Nov 12, 2024 | IOVA IOVANCE BIOTHERAPEUTICS, INC. | Sale(S) | 50,000 | $10.06 | $503,000 | Direct |
1-5 of 5 transactions
About Maynard Ryan D
Maynard Ryan D (SEC CIK 0001363984) files insider reports with the SEC as Director of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Chief Financial Officer of Foghorn Therapeutics Inc. (FHTX).
Signal8 holds 5 ownership filings by Maynard Ryan D (1 Form 3, 4 Form 4), filed between Nov 14, 2024 and Jun 18, 2026. Those filings report 5 transactions, from Nov 12, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Maynard Ryan D's filings is in SAN CARLOS, CA.
Recent filings by Maynard Ryan D
- Jun 16, 2026: Grant or award of IOVA derivative securities (Form 4, code A).
- Feb 23, 2026: Grant or award of FHTX derivative securities (Form 4, code A).
- Jun 13, 2025: Grant or award of IOVA derivative securities (Form 4, code A).
- Nov 12, 2024: Option exercise of IOVA shares (Form 4, code M).
- Nov 12, 2024: Open-market sale of IOVA shares (Form 4, code S).
Other insiders filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
- Berkowitz Noah, Chief Medical Officer
- Vogt Frederick G, Interim CEO & General Counsel
- BILINSKY IGOR, Chief Operating Officer
- Puri Raj K., Chief Regulatory Officer
- Kirby Daniel Gordon, Chief Commercial Officer
- Roche Corleen M., Chief Financial Officer